Hepatitis C virus drug resistance associated substitutions and their clinical relevance: Update 2018

被引：151

作者：

Sorbo, Maria C. ^{[1
]}

Cento, Valeria ^{[4
]}

Di Maio, Velia C. ^{[1
]}

Howe, Anita Y. M. ^{[2
]}

Garcia, Federico ^{[3
]}

Perno, Carlo F. ^{[5
]}

Ceccherini-Silberstein, Francesca ^{[1
]}

机构：

[1] Univ Roma Tor Vergata, Dept Expt Med & Surg, Rome, Italy

[2] St Pauls Hosp, Ctr Excellence HIV AIDS, Vancouver, BC, Canada

[3] Hosp Univ San Cecilia, Clin Microbiol Serv, Granada, Spain

[4] Univ Milan, Residency Program Microbiol & Virol, Milan, Italy

[5] Univ Milan, Dept Oncol & Oncohematol, Milan, Italy

来源：

DRUG RESISTANCE UPDATES | 2018年 / 37卷

关键词：

Direct acting antiviral agents; Treatment failure; Fold-change; HCV genotypic resistance testing; HCV sequencing; GENOTYPE; 1; INFECTION; TREATMENT-EXPERIENCED PATIENTS; NS3/4A PROTEASE INHIBITOR; DACLATASVIR PLUS ASUNAPREVIR; TREATMENT-NAIVE PATIENTS; HCV NS5A INHIBITOR; IN-VITRO ACTIVITY; DIRECT-ACTING ANTIVIRALS; ADVANCED LIVER-DISEASE; ONCE-DAILY SIMEPREVIR;

D O I：

10.1016/j.drup.2018.01.004

中图分类号：

R9 [药学];

学科分类号：

1007 ;

摘要：

Nowadays, due to the development of potent Direct-Acting Antiviral Agents (DAM) that specifically target NS3, NS5A and NS5B viral proteins, several new and highly efficacious options to treat chronic Hepatitis C virus (HCV) infection are available. The natural presence of resistance associated substitutions (RASs), as well as their rapid emergence during incomplete drug-pressure, are intrinsic characteristics of HCV that greatly affect treatment outcome and the chances to achieve a virolgical cure. To date, a high number of RASs in NS3, NS5A, and NS5B have been associated in vivo and/or in vitro with reduced susceptibility to DAM, but no comprehensive RASs list is available. This review thus provides an updated, systematic overview of the role of RASs to currently approved DAM or in phase II/III of clinical development against HCV-infection, discriminating their impact in different HCV-genotypes and DAM, providing assistance for a fruitful use of HCV resistance testing in clinical practice.

引用

页码：17 / 39

页数：23

共 182 条

[1]

Abergel A, 2016, HEPATOLOGY

[2] Ledipasvir and Sofosbuvir for Untreated HCV Genotype 1 Infection [J].

Afdhal, Nezam ;

Zeuzem, Stefan ;

Kwo, Paul ;

Chojkier, Mario ;

Gitlin, Norman ;

Puoti, Massimo ;

Romero-Gomez, Manuel ;

Zarski, Jean-Pierre ;

Agarwal, Kosh ;

Buggisch, Peter ;

Foster, Graham R. ;

Braeu, Norbert ;

Buti, Maria ;

Jacobson, Ira M. ;

Subramanian, G. Mani ;

Ding, Xiao ;

Mo, Hongmei ;

Yang, Jenny C. ;

Pang, Phillip S. ;

Symonds, William T. ;

McHutchison, John G. ;

Muir, Andrew J. ;

Mangia, Alessandra ;

Marcellin, Patrick .

NEW ENGLAND JOURNAL OF MEDICINE, 2014, 370 (20) :1889-1898

[3] Evaluating the Role of Macrocycles in the Susceptibility of Hepatitis C Virus NS3/4A Protease Inhibitors to Drug Resistance [J].

Ali, Akbar ;

Aydin, Cihan ;

Gildemeister, Reinhold ;

Romano, Keith P. ;

Cao, Hong ;

Oezen, Ayseguel ;

Soumana, Djade ;

Newton, Alicia ;

Petropoulos, Christos J. ;

Huang, Wei ;

Schiffer, Celia A. .

ACS CHEMICAL BIOLOGY, 2013, 8 (07) :1469-1478

[4] ABT-450, Ritonavir, Ombitasvir, and Dasabuvir Achieves 97% and 100% Sustained Virologic Response With or Without Ribavirin in Treatment-Experienced Patients With HCV Genotype 1b Infection [J].

Andreone, Pietro ;

Colombo, Massimo G. ;

Enejosa, Jeffrey V. ;

Koksal, Iftihar ;

Ferenci, Peter ;

Maieron, Andreas ;

Muellhaupt, Beat ;

Horsmans, Yves ;

Weiland, Ola ;

Reesink, Henk W. ;

Rodrigues, Lino, Jr. ;

Hu, Yiran B. ;

Podsadecki, Thomas ;

Bernstein, Barry .

GASTROENTEROLOGY, 2014, 147 (02) :359-+

[5]

[Anonymous], 2018, Recommendations for testing, managing, and treating hepatitis C

[6]

[Anonymous], J HEPATOL

[7]

Asante-Appiah E., 2016, J HEPATOLOGY

[8]

Asante-Appiah E, 2017, ANTIMICROB AGENTS CH, V61, DOI [10.1128/aac.00363-17, 10.1128/AAC.00363-17]

[9] Susceptibility of Treatment-Naive Hepatitis C Virus (HCV) Clinical Isolates to HCV Protease Inhibitors [J].

Bae, Andrew ;

Sun, Siu-Chi ;

Qi, Xiaoping ;

Chen, Xiaowu ;

Ku, Karin ;

Worth, Angela ;

Wong, Kelly A. ;

Harris, Jeanette ;

Miller, Michael D. ;

Mo, Hongmei .

ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2010, 54 (12) :5288-5297

[10] Emergence of resistance-associated variants after failed triple therapy with vaniprevir in treatment-experienced non-cirrhotic patients with hepatitis C-genotype 1 infection: A population and clonal analysis [J].

Barnard, Richard J. O. ;

McHale, Carolyn M. ;

Newhard, William ;

Cheney, Carol A. ;

Graham, Donald J. ;

Himmelberger, Amy L. ;

Strizki, Julie ;

Hwang, Peggy M. T. ;

Rivera, Amber A. ;

Reeves, Jacqueline D. ;

Nickle, David ;

DiNubile, Mark J. ;

Hazuda, Dania J. ;

Mobashery, Niloufar .

VIROLOGY, 2013, 443 (02) :278-284

← 1 2 3 4 5 6 7 8 9 10 →